CN108902987A - 乳矿物盐氨糖软骨素维d胶囊 - Google Patents
乳矿物盐氨糖软骨素维d胶囊 Download PDFInfo
- Publication number
- CN108902987A CN108902987A CN201810630758.1A CN201810630758A CN108902987A CN 108902987 A CN108902987 A CN 108902987A CN 201810630758 A CN201810630758 A CN 201810630758A CN 108902987 A CN108902987 A CN 108902987A
- Authority
- CN
- China
- Prior art keywords
- parts
- mineral salt
- capsule
- chondroitin
- newborn mineral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 44
- 239000011707 mineral Substances 0.000 title claims abstract description 44
- 150000003839 salts Chemical class 0.000 title claims abstract description 43
- 239000002775 capsule Substances 0.000 title claims abstract description 30
- 229920002567 Chondroitin Polymers 0.000 title claims abstract description 25
- 229910021529 ammonia Inorganic materials 0.000 title claims abstract description 25
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 title claims abstract description 24
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 48
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 28
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 24
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 19
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 19
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 229960003563 calcium carbonate Drugs 0.000 claims abstract description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 12
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 12
- 239000011812 mixed powder Substances 0.000 claims description 12
- 239000011710 vitamin D Substances 0.000 claims description 12
- 235000019166 vitamin D Nutrition 0.000 claims description 12
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 12
- 229940046008 vitamin d Drugs 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000011049 filling Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 235000020985 whole grains Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000011122 softwood Substances 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000037182 bone density Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 239000011647 vitamin D3 Substances 0.000 abstract description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 29
- 239000011575 calcium Substances 0.000 description 29
- 229910052791 calcium Inorganic materials 0.000 description 29
- 210000000988 bone and bone Anatomy 0.000 description 10
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010020100 Hip fracture Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229940069978 calcium supplement Drugs 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- -1 D- glucosamine hydrochloric acid Salt Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JETSKDPKURDVNI-UHFFFAOYSA-N [C].[Ca] Chemical compound [C].[Ca] JETSKDPKURDVNI-UHFFFAOYSA-N 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940092124 calcium citrate malate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical class O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种乳矿物盐氨糖软骨素维D胶囊,该胶囊由乳矿物盐、D‑氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素、维生素D3粉、微晶纤维素、硬脂酸镁制成,本发明还公开了乳矿物盐氨糖软骨素维D胶囊的制备方法。本发明的乳矿物盐氨糖软骨素维D胶囊兼具有乳矿物盐、D‑氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素、维生素D3的各种功效,适合中老年人群服用,可增加服用者的骨密度。
Description
技术领域
本发明涉及一种胶囊,具体来说,涉及一种乳矿物盐氨糖软骨素维D胶囊。
背景技术
骨质疏松症,是多种原因引起的一种骨病,骨组织有正常的钙化,钙盐与基质呈正常比例,以单位体积内骨组织量减少为特点的代谢性骨病变。在多数骨质疏松中,骨组织的减少主要由于骨质吸收增多所致。以骨骼疼痛、易于骨折为特征。
适量钙剂在生物力学方面能够提高骨生物力学指标,促进骨折愈合,对防治骨质疏松骨折起着积极的作用。钙作为防治骨质疏松的基础用药,已广 泛应用于人们的生活和临床实践中。但近年来多项研究均提出了高钙补充将会导致骨质疏松髋部骨折的发生率明显上升,这应引起全社会的高度重视。
软骨的细胞外基质主要由胶原蛋白(collagen)和糖蛋白(PG)组成。PG中,糖胺多糖(GAG)主要由硫酸软骨素、透明质酸(HA)和硫酸角质素组成。活的软骨细胞在不断地更新其细胞外基质,并保持PG和胶原成分的相对稳定。软骨内PG含量减少,特别是GAG含量的减少,也会使软骨力学特性改变。
发明内容
针对相关技术中的上述技术问题,本发明提出一种乳矿物盐氨糖软骨素维D胶囊,能够克服现有技术的上述不足。
为实现上述技术目的,本发明的技术方案是这样实现的:
一种乳矿物盐氨糖软骨素维D胶囊,包括如下重量份的组分:
乳矿物盐 170-220份
D-氨基葡萄糖盐酸盐 60-120份
碳酸钙 50-110份
硫酸软骨素 30-60份
质量含量为0.25%的维生素D3粉 0.2-0.6份
微晶纤维素 20-40份
硬脂酸镁 2-4份。
优选地,乳矿物盐氨糖软骨素维D胶囊包括如下重量份的组分:
乳矿物盐 200份
D-氨基葡萄糖盐酸盐 90份
碳酸钙 90份
硫酸软骨素 45份
质量含量为0.25%的维生素D3粉 0.4份
微晶纤维素 21.6份
硬脂酸镁 3份。
根据本发明的另一方面,提供了乳矿物盐氨糖软骨素维D胶囊的制备方法,包括如下步骤:
(1)过筛
将乳矿物盐、D-氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素、质量含量为0.25%的维生素D3粉、微晶纤维素、硬脂酸镁分别过60目筛;
(2)混合
将过筛后的维生素D3粉与微晶纤维素按等量递增法混合均匀得到混合粉1,将混合粉1与乳矿物盐、D-氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素用混合机混合20分钟得到混合粉2;
(3)制粒
将步骤(2)最终所得混合粉2中加入适量水,制成软材,然后用18目筛网制粒,得到湿颗粒;
(4)干燥
将步骤(3)得到的湿颗粒使用流化床进行干燥,干燥温度设定为50℃,水分控制在5.0% 以内,干燥时间2小时得到干颗粒;
(5)整粒
将步骤(4)所得干颗粒过16目筛网进行整粒;
(6)总混
将步骤(5)所得颗粒置入混合机中,加入硬脂酸镁,混合5分钟得到总混合颗粒;
(7)灌装
将步骤(6)所得总混合颗粒灌装胶囊,调节装量为0.45g/粒。
本发明的乳矿物盐氨糖软骨素维D胶囊中各组分的药理作用:
乳矿物盐又名乳钙、乳清矿物质浓缩物、乳清钙,来源于牛乳,是将牛乳通过膜渗透、分离、浓缩和喷雾干燥等工艺处理后得到的乳白色粉末其主要成分是磷酸钙除此之外还包括蛋白质、乳糖及锌、磷、钠、钾、镁、等丰富的营养成分,其钙磷比较利于人体的吸收利用,作为一种新的钙源被广泛用于各种食品,是消化吸收和营养价值最好的钙源。补钙效果不会发生逆转,增加的骨密度即使在停止补充乳矿物盐三年后依然保持,而无机钙停止补充后已增加的骨密度会逐渐消失。
D-氨基葡萄糖盐酸盐是甲壳素在盐酸中经充分降解得到的壳寡糖衍生物,能促进人体黏多糖合成,提高关节滑液黏性,有利于关节软骨的代谢和修复,并有明显的消炎镇痛作用,具有抗炎、抗肿瘤、免疫调节、增加骨密度、防腐抗菌等药理作用。
碳酸钙可作补钙剂,吸收率可达39%,仅次于果酸钙可溶于胃酸,已成为剂型最多、应用最多的补钙剂。
硫酸软骨素是共价连接在蛋白质上形成蛋白聚糖的一类糖胺聚糖。硫酸软骨素广泛分布于动物组织的细胞外基质和细胞表面,糖链由交替的葡萄糖醛酸和N-乙酰半乳糖胺(又称N-乙酰氨基半乳糖)二糖单位组成,通过一个似糖链接区连接到核心蛋白的丝氨酸残基上。在医学上作为治疗关节疾病的药品,可以提高关节活动度,减小关节间隙的宽度,从根本上改善关节问题。
维生素D3能提高机体对钙、磷的吸收,使血浆钙和血浆磷的水平达到饱和程度,消除钙剂导致骨质疏松髋部骨折的发生率上升的副作用。
本发明的有益效果:
钙剂采用乳矿物盐和碳酸钙既可以提高钙的吸收利用率又可以降低成本;加入维生素D3能消除高量摄入钙剂导致骨质疏松髋部骨折的发生率上升的副作用;D-氨基葡萄糖盐酸盐与硫酸软骨素联合使用,能延缓和抑制关节软骨组织的退行性变。本发明的乳矿物盐氨糖软骨素维D胶囊适合中老年人群服用,可增加服用者的骨密度。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是根据本发明实施例所述的乳矿物盐氨糖软骨素维D胶囊的制备方法图;
注:图1中虚线内为10万级洁净区。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
乳矿物盐氨糖软骨素维D胶囊的组分:
乳矿物盐 200g
D-氨基葡萄糖盐酸盐 90g
碳酸钙 90g
硫酸软骨素 45g
质量含量为0.25%的维生素D3粉 0.4g
微晶纤维素 21.6g
硬脂酸镁 3g
制备工艺如图1所示,(1)将乳矿物盐、D-氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素、维生素D3质量含量为0.25%的维生素D3粉、微晶纤维素、硬脂酸镁分别过60目筛;(2)将过筛后的维生素D3粉与微晶纤维素按等量递增法混合均匀得到混合粉1,将混合粉1与乳矿物盐、D-氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素用混合机混合20分钟得到混合粉2;(3)将步骤(2)最终所得混合粉2中加入适量水,制成软材,然后用18目筛网制粒,得到湿颗粒;(4)将步骤(3)得到的湿颗粒使用流化床进行干燥,干燥温度设定为50℃,水分控制在5.0% 以内,干燥时间2小时得到干颗粒;(5)将步骤(4)所得干颗粒过16目筛网进行整粒;(6)将步骤(5)所得颗粒置入混合机中,加入硬脂酸镁,混合5分钟得到总混合颗粒;(7)将步骤(6)所得总混合颗粒灌装胶囊,调节装量为0.45g/粒。
实施例2
乳矿物盐氨糖软骨素维D胶囊的组分:
乳矿物盐 170g
D-氨基葡萄糖盐酸盐 60g
碳酸钙 110g
硫酸软骨素 60g
质量含量为0.25%的维生素D3粉 0.6g
微晶纤维素 20g
硬脂酸镁 2g
按照实施例1所述制备工艺制备得到乳矿物盐氨糖软骨素维D胶囊。
实施例3
乳矿物盐氨糖软骨素维D胶囊的组分:
乳矿物盐 220g
D-氨基葡萄糖盐酸盐 120g
碳酸钙 50g
硫酸软骨素 30g
质量含量为0.25%的维生素D3粉 0.2g
微晶纤维素 40g
硬脂酸镁 4g
按照实施例1所述制备工艺制备得到乳矿物盐氨糖软骨素维D胶囊。
增加骨密度功能动物实验
SPF级雌性离乳SD大鼠根据体重随机分为下列五组:低钙对照组,本发明的乳矿物盐氨糖软骨素维D胶囊250mg/kg.bw组,500mg/kg.bw组和1500mg/kg.bw组,碳素钙对照组,每组10只动物。三个剂量组以相应剂量的乳矿物盐氨糖软骨素维D胶囊水溶液灌胃,碳酸钙对照组经口灌入525mg/kg.bw的碳酸钙,低钙对照组以蒸馏水灌胃。试验3周后将动物进行3天钙吸收实验,测摄食量、饲料和粪便钙含量,计算表观钙吸收率。实验期13周。实验末处死动物取双侧股骨:测定右股骨钙含量和左股骨的骨密度。
钙吸收实验结果显示受试物三个剂量组的身长与低钙对照组比较无显著性差异,高剂量组实验末期体重显著高于低钙对照组。受试物低、中剂量组的钙表观吸收率均显著高于碳酸钙对照组,表明该样品钙吸收率较高。
三个剂量组和碳酸钙对照组的实验前体重与低钙对照组比较无显著差异;中、高剂量组的实验末体重与低钙对照组比较无显著性差异。乳矿物盐氨糖软骨素维D胶囊三个剂量组以及碳酸钙对照组的左股骨骨密度,右股骨骨钙含量,中、高剂量组的骨重与低钙对照组比较均显著增加。受试物高剂量组的右股骨骨重、体重与碳酸钙对照组比较显著增加,其余指标与碳酸钙对照组比较均无显著性差异。
按评价标准:本发明的乳矿物盐氨糖软骨素维D胶囊钙吸收率较高,具有增加骨密度的功能。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (3)
1.一种乳矿物盐氨糖软骨素维D胶囊,其特征在于,包括如下重量份的组分:
乳矿物盐 170-220份
D-氨基葡萄糖盐酸盐 60-120份
碳酸钙 50-110份
硫酸软骨素 30-60份
质量含量为0.25%的维生素D3粉 0.2-0.6份
微晶纤维素 20-40份
硬脂酸镁 2-4份。
2.根据权利要求1所述的乳矿物盐氨糖软骨素维D胶囊,其特征在于,包括如下重量份的组分:
乳矿物盐 200份
D-氨基葡萄糖盐酸盐 90份
碳酸钙 90份
硫酸软骨素 45份
质量含量为0.25%的维生素D3粉 0.4份
微晶纤维素 21.6份
硬脂酸镁 3份。
3.根据权利要求1所述的乳矿物盐氨糖软骨素维D胶囊的制备方法,其特征在于,包括如下步骤:
(1)过筛
将乳矿物盐、D-氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素、质量含量为0.25%的维生素D3粉、微晶纤维素、硬脂酸镁分别过60目筛;
(2)混合
将过筛后的维生素D3粉与微晶纤维素按等量递增法混合均匀得到混合粉1,将混合粉1与乳矿物盐、D-氨基葡萄糖盐酸盐、碳酸钙、硫酸软骨素用混合机混合20分钟得到混合粉2;
(3)制粒
将步骤(2)最终所得混合粉2中加入适量水,制成软材,然后用18目筛网制粒,得到湿颗粒;
(4)干燥
将步骤(3)得到的湿颗粒使用流化床进行干燥,干燥温度设定为50℃,水分控制在5.0% 以内,干燥时间2小时得到干颗粒;
(5)整粒
将步骤(4)所得干颗粒过16目筛网进行整粒;
(6)总混
将步骤(5)所得颗粒置入混合机中,加入硬脂酸镁,混合5分钟得到总混合颗粒;
(7)灌装
将步骤(6)所得总混合颗粒灌装胶囊,调节装量为0.45g/粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810630758.1A CN108902987A (zh) | 2018-06-19 | 2018-06-19 | 乳矿物盐氨糖软骨素维d胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810630758.1A CN108902987A (zh) | 2018-06-19 | 2018-06-19 | 乳矿物盐氨糖软骨素维d胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108902987A true CN108902987A (zh) | 2018-11-30 |
Family
ID=64421844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810630758.1A Pending CN108902987A (zh) | 2018-06-19 | 2018-06-19 | 乳矿物盐氨糖软骨素维d胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108902987A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101904866A (zh) * | 2010-09-07 | 2010-12-08 | 许阳 | 一种治疗骨质疏松的药物组合物及其制备方法 |
CH703348A1 (de) * | 2010-06-29 | 2011-12-30 | Mepha Gmbh | Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen. |
CN104382005A (zh) * | 2013-08-19 | 2015-03-04 | 宣城柏维力生物工程有限公司 | 一种氨糖软骨素胶原蛋白片及其制备方法 |
CN104432029A (zh) * | 2014-11-17 | 2015-03-25 | 威海桦众节能设备有限公司 | 一种增加骨密度的保健食品 |
CN104664402A (zh) * | 2015-03-26 | 2015-06-03 | 江苏康缘药业股份有限公司 | 一种增加骨密度的组合物及其制备方法和应用 |
CN105942501A (zh) * | 2016-05-03 | 2016-09-21 | 宣城柏维力生物工程有限公司 | 一种增加骨密度片及其制备方法 |
-
2018
- 2018-06-19 CN CN201810630758.1A patent/CN108902987A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH703348A1 (de) * | 2010-06-29 | 2011-12-30 | Mepha Gmbh | Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen. |
CN101904866A (zh) * | 2010-09-07 | 2010-12-08 | 许阳 | 一种治疗骨质疏松的药物组合物及其制备方法 |
CN104382005A (zh) * | 2013-08-19 | 2015-03-04 | 宣城柏维力生物工程有限公司 | 一种氨糖软骨素胶原蛋白片及其制备方法 |
CN104432029A (zh) * | 2014-11-17 | 2015-03-25 | 威海桦众节能设备有限公司 | 一种增加骨密度的保健食品 |
CN104664402A (zh) * | 2015-03-26 | 2015-06-03 | 江苏康缘药业股份有限公司 | 一种增加骨密度的组合物及其制备方法和应用 |
CN105942501A (zh) * | 2016-05-03 | 2016-09-21 | 宣城柏维力生物工程有限公司 | 一种增加骨密度片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102318835B (zh) | 一种减少骨质流失的组合物及其制备方法 | |
CN102224896B (zh) | 用于增加人体免疫力及增加骨密度的保健食品及制备方法 | |
CN101559218B (zh) | 一种具有增加骨密度功能的组合物 | |
CN102894372A (zh) | 一种增加骨密度的保健食品及其制备方法 | |
CA2539919A1 (en) | Compositions of aminosugars or fragments of glycosaminoglycans with s-adenosylmethionine for the treatment or repair of connective tissue in mammals | |
AU2011336145C1 (en) | Galenic composition suitable for administration to a non-human animal, uses thereof, and associated methods | |
CN104939054A (zh) | 一种增强骨密度及免疫力的保健食品及其制备方法 | |
EP2916855A1 (de) | Kollagenhydrolysat und dessen verwendung | |
CN106235311A (zh) | 一种促进骨骼系统健康的组合物及其应用 | |
JP2010505818A (ja) | 甲殻類の胃石成分を含む組成物とその使用 | |
KR100961291B1 (ko) | 골다공증 치료용 조성물의 제조에 사용되는 글루타메이트,글루타메이트 유도체 또는 대사산물, 글루타메이트 유사체또는 이들의 혼합물의 용도 | |
CN103143001B (zh) | 一种骨胶原高钙片 | |
CN106213492A (zh) | 一种提升运动机能并增加骨密度的健康产品及制备方法 | |
WO2013136871A1 (ja) | 過硫酸化コンドロイチン組成物 | |
CN109276710A (zh) | 一种增加骨密度的组合物及其制备方法和用途 | |
KR20140075844A (ko) | 알긴산을 포함하는 골관절염 예방 또는 치료용 조성물 | |
CN105079028A (zh) | 一种改善骨关节的保健品及其制备方法 | |
CN108619493A (zh) | 一种增加骨密度的胶囊 | |
CN108902987A (zh) | 乳矿物盐氨糖软骨素维d胶囊 | |
CN110946994A (zh) | 一种增加骨密度的组合物及其制备方法 | |
CN110226734A (zh) | 一种具有人体肠道调养作用的调味盐及其制备方法 | |
CN101032523B (zh) | 一种蜂王浆酸钙及其制备方法 | |
CN108815505A (zh) | 提高中老年人骨密度和骨关节功能避免腰腿抽筋的组合物 | |
CN104523804B (zh) | 一种增加骨密度的胶囊及其制备方法 | |
CN102626420B (zh) | 一种含有锶、钙和维生素d的混合制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181130 |
|
RJ01 | Rejection of invention patent application after publication |